SoFi Technologies Inc vs Viatris Inc — how do they compare? SoFi Technologies Inc trades at $17.38 (market cap $23.26B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: SoFi Technologies Inc is the larger of the two by market cap, and Viatris Inc pays a 2.89% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals.
| SOFI | VTRS | |
|---|---|---|
Market Cap | $23.26B | $19.09B |
Sector | Financials | Health |
52-Week High | $32.21 | $17.86 |
52-Week Low | $15.15 | $9.49 |
Enterprise Value | — | $31.21B |
Dividend Yield | — | 2.89% |
Signals from Pluang's Aura AI — not financial advice
SOFI stock trades at $18.01, down 1.15% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with $0.12 EPS, and revenue growth remains robust at 40% year-over-year. Recent news highlights a partnership with Payward to enhance banking and digital asset connectivity, though the stock faces pressure from rising Treasury yields affecting fintech lenders.
The outlook is mixed; solid fundamentals and growth support upside toward the $20.63 consensus target, but risks include negative operating cash flow, high leverage, and macroeconomic sensitivity. Investors should weigh the company's expansion against persistent profitability challenges and competitive fintech pressures.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Trailing returns across standard periods
Latest headlines on both assets
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →